Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)
Description: Zavesca, a medication already approved for treating a rare genetic disorder, works as a male contraceptive for a particular strain of laboratory mouse. Exactly how Zavesca acts as a contraceptive for the mice is not known.
Delivery Method: Oral
Duration Type: Permanent
Active Pharmaceutical Ingredient (API):
Multipurpose Preventive Technology (MPT): No
Project Phase: Discovery and Early Development
Development Stage: Lead Optimization
Active Development: No
- Research on Zavesca as a male contraceptive has stopped as it was shown to not be effective in humans.